Biopsy-based algorithm found accurate for small renal masses

February 9, 2013
Biopsy-based algorithm found accurate for small renal masses
Compared with final pathology, biopsy of small renal masses can be accurately used in a treatment algorithm to direct management, according to research published in the February issue of The Journal of Urology.

(HealthDay)—Compared with final pathology, biopsy of small renal masses (SRMs) can be accurately used in a treatment algorithm to direct management, according to research published in the February issue of The Journal of Urology.

Schuyler J. Halverson, M.D., of the University of Michigan Health System in Ann Arbor, and colleagues assessed the accuracy of a biopsy-directed treatment algorithm for correctly assigning 133 patients with SRMs (≤4 cm) to treatment or active surveillance.

Using a biopsy-directed treatment algorithm, 36 patients with SRMs were assigned to surveillance and 97 were treated. Based on the final , the researchers found that 31 percent of those patients for whom surveillance was recommended should have received treatment, while no patients moved from treatment to surveillance. Seven of the 11 misclassified cases had a biopsy indicative of grade 1 clear cell , which was upgraded to grade 2 or 3. Overall agreement between biopsy and final pathology was 92 percent; however, after adjustment of the algorithm to avoid undergrading of clear cell renal cancer, agreement improved to 97 percent, with negative and positive predictive values of 0.86 and 1.0, respectively.

"Image guided, percutaneous renal mass biopsy is highly accurate for diagnosis in most patients and provides valuable information to guide the management of SRM," the authors write. "We have shown that although slight may exist between initial biopsy and final pathology due to the heterogeneous nature of some tumors, this variability becomes clinically irrelevant when using a well-defined management protocol."

Explore further: Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer

More information: Abstract
Full Text

Related Stories

Criteria for surveillance of small renal mass examined

May 7, 2012

(HealthDay) -- Active surveillance of patients with small renal masses is driven by a tumor size less than 3 cm, poor performance score (PS), and an endophytic lesion, among other patient, tumor, and surgeon characteristics, ...

Active surveillance cost-effective for prostate cancer

July 13, 2012

(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, according ...

Recommended for you

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.